View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 4, 2021updated 11 Jul 2022 2:19pm

Inovio obtains approval for Phase III trial of Covid-19 vaccine in India

The trial will evaluate the efficacy of two doses of INO-4800 administered one month apart in adult subjects. 

The Drug Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) has granted authorisation to advance the Phase III portion of Inovio’s international Phase II/III clinical trial for its Covid-19 vaccine candidate, INO-4800, in the country.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The vaccine contains a well-designed deoxyribonucleic acid (DNA) plasmid and is administered intradermally, following electroporation using a smart device.

This device can deliver the DNA plasmid into body cells to stimulate a well-tolerated immune response.

Inovio will carry out the Phase III INNOVATE trial in collaboration with Advaccine Biopharmaceuticals Suzhou in various countries in Latin America, Africa and Asia.

The Phase III trial will investigate the efficacy of two 2mg doses of INO-4800 given at a one-month interval in adult subjects aged 18 years and above.

Virologically established symptomatic Covid-19 will be the trial’s primary goal.

Inovio commenced Phase III trial in various other countries on obtaining favourable data from Phase II US trial.

INO-4800 was found to be well-tolerated and immunogenic in adults, interim data from the Phase II trial showed.

Inovio president and CEO Dr J Joseph Kim said: “As Covid-19 continues to threaten the health and safety of the global population, and many areas of the world are still awaiting sufficient access to safe and effective vaccines, Inovio is pleased to receive regulatory authorisation to proceed with our efficacy Phase III trial in India.

“Inovio remains steadfast in its mission to fight Covid-19 through the development of INO-4800, which is designed to serve the needs of those in India and beyond, as both a primary series and a booster vaccine.”

Inovio obtained Colombia’s National Food and Drug Surveillance Institute (INVIMA) authorisation to conduct the trial last month.

The company also received regulatory authorisation from health agencies in Brazil, the Philippines, and Mexico for the trial.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena